Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Capital Leases (2021 - 2022)

Elicio Therapeutics filings provide 2 years of Capital Leases readings, the most recent being $168000.0 for Q4 2022.

  • On a quarterly basis, Capital Leases fell 28.51% to $168000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $168000.0, a 28.51% decrease, with the full-year FY2022 number at $168000.0, down 28.51% from a year prior.
  • Capital Leases hit $168000.0 in Q4 2022 for Elicio Therapeutics, down from $186000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $235000.0 in Q4 2021 to a low of $168000.0 in Q4 2022.